GCCs – Indian Pharma moves up the Value Chain – Sanofi, Amgen, Eli Lilly, J&J and others are investing billions in India’s new breed of Global Capability Centres For decades, multinational pharma companies viewed India through a single lens — low-cost manufacturing and generic scale. Those days are gone. The India footprint has steadily climbed…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
